Award
NIH Reporter #5F31CA301949-02
The Development of Selective Inhibitors to Oncogenic Rac1 Variants
Recipient
University of California, San Francisco
Award Amount
$42,853.00
Ceiling
$42,853.00
Awarded
August 14, 2026
Identifier
5F31CA301949-02
Award to University of California, San Francisco for developing selective inhibitors targeting oncogenic Rac1 variants implicated in cancer progression and drug resistance, with a total award amount of $42,853 for fiscal year 2026.
Description
This project aims to develop chemical tools to distinguish the roles of oncogenic Rac1 variants in cancer progression and to identify targeted therapeutic strategies for their selective inhibition. It involves structure-based drug design, covalent inhibitor development, and CRISPR Prime editing to assess compound efficacy in cellular models, focusing on elucidating Rac1 isoforms’ roles in oncogenesis and developing targeted therapies for cancers involving these variants.